Repligen amends $287.5 million 0.375% convertibles due July 2024

By Rebecca Melvin

Concord, N.H., March 8 – Repligen Corp. amended on Friday the indenture for its $287.5 million of 0.375% convertible notes due July 15, 2024, according to an 8-K filed with the Securities and Exchange Commission.

Under the second supplemental indenture between the company and Wilmington Trust NA as trustee, the company has elected combination settlement of cash and shares upon conversion. The notes will be convertible prior to April 15, 2024 at the option of holders only upon satisfaction of certain conditions and during certain periods. After April 15, 2024, the notes will be convertible at any time.

The notes were issued July 19, 2019 via J.P. Morgan Securities LLC as the bookrunner for the registered offering.

They are non-callable and have no put features. They priced concurrently with a $120 million common stock offering, which has a 207,000 share greenshoe, and the shares priced at $87.00 each.

Repligen is a Waltham, Mass-based bioprocessing company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.